Want to see AARD full AI Analyst Report?
Top Page
Aardvark Therapeutics, Inc.
(NASDAQ:AARD)
Select Model
Select Model
Rating:44Neutral
Price Target:
$1.50
▼(-73.82% Downside)
Action:Reiterated
Date:10/24/26
The score is held down primarily by weak financial performance (no revenue, widening losses, heavy cash burn) and a strongly bearish technical picture (price far below major moving averages with negative MACD). Positive corporate developments—especially the FDA clinical hold lift—provide some upside optionality, but they do not offset the current funding and execution risks implied by the financials.
Positive Factors
Low financial leverage
Very low debt relative to equity reduces near-term solvency pressure and preserves flexibility in financing and capital allocation. This gives Aardvark more room to manage development spending and pursue its lead program without the added constraints of a heavily leveraged balance sheet.
Negative Factors
No revenue and widening losses
Aardvark has not yet established commercial revenue or operating leverage, while losses have expanded sharply from prior periods. Continued negative profitability leaves the business dependent on successful development and eventual commercialization before it can build a self-sustaining earnings base.
Read all positive and negative factors
Positive Factors
Negative Factors
Low financial leverage
Very low debt relative to equity reduces near-term solvency pressure and preserves flexibility in financing and capital allocation. This gives Aardvark more room to manage development spending and pursue its lead program without the added constraints of a heavily leveraged balance sheet.
Read all positive factors
Aardvark Therapeutics, Inc. (AARD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$30.42M
Dividend YieldN/A
Average Volume (3M)132.28K
Price to Earnings (P/E)―
Beta (1Y)2.56
Revenue GrowthN/A
EPS Growth-89.45%
CountryUS
Employees28
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.21
Shares Outstanding21,884,846
10 Day Avg. Volume148,250
30 Day Avg. Volume132,279
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)2.69
Price to Sales (P/S)0.00
P/FCF Ratio-5.28
Enterprise Value/Market Cap1.73
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.75
Forecast
1Y Price Target
$3.88Price Target Upside-32.37% Downside
Rating ConsensusHold
Number of Analyst Covering7
EPS Forecast (FY)-3.12
Revenue Forecast (FY)N/A
Aardvark Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic p...
How the Company Makes Money
null...
Aardvark Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
64
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -69.85M | -57.55M | -22.65M | -6.56M | -10.76M |
| Net Income | -69.89M | -57.59M | -20.59M | -7.21M | -13.56M |
Balance Sheet | |||||
| Total Assets | 81.46M | 117.18M | 77.51M | 10.54M | 16.76M |
| Cash, Cash Equivalents and Short-Term Investments | 73.87M | 110.03M | 73.66M | 9.99M | 16.11M |
| Total Debt | 677.00K | 441.00K | 779.00K | 162.00K | 262.00K |
| Total Liabilities | 6.66M | 10.55M | 132.15M | 45.34M | 44.68M |
| Stockholders Equity | 74.80M | 106.63M | -54.64M | -34.80M | -27.92M |
Cash Flow | |||||
| Free Cash Flow | -69.41M | -54.27M | -18.20M | -5.82M | -10.54M |
| Operating Cash Flow | -69.41M | -54.17M | -18.09M | -5.82M | -10.54M |
| Investing Cash Flow | 116.55M | -49.67M | -12.00M | 0.00 | -1.00M |
| Financing Cash Flow | 711.00K | 89.25M | 81.99M | 0.00 | 225.00K |
Aardvark Therapeutics, Inc. Technical Analysis
Negative
5.73
Price Trends
5.28
Negative
5.42
Negative
6.66
Negative
Market Momentum
-0.62
Positive
20.32
Positive
29.10
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AARD, the sentiment is Negative. The current price of 5.73 is above the 20-day moving average (MA) of 4.41, above the 50-day MA of 5.28, and below the 200-day MA of 6.66, indicating a bearish trend. The MACD of -0.62 indicates Positive momentum. The RSI at 20.32 is Positive, neither overbought nor oversold. The STOCH value of 29.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AARD.
Aardvark Therapeutics, Inc. Risk Analysis
Aardvark Therapeutics, Inc. disclosed 90 risk factors in its most recent earnings report. Aardvark Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
We may use certain artificial intelligence (AI) technologies, which present risks and challenges that could adversely impact our business. Q2, 2026
Aardvark Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
47 Neutral | $183.84M | -2.17 | 44.63% | ― | 3.03% | 57.71% | |
45 Neutral | $135.55M | -0.69 | -1032.19% | ― | 354.37% | -63.33% | |
45 Neutral | $77.99M | -4.80 | -41.15% | ― | -100.00% | 64.23% | |
44 Neutral | $30.42M | -0.43 | -71.54% | ― | ― | -89.45% | |
42 Neutral | $11.74M | -0.02 | 77.63% | ― | 6.81% | 11.95% | |
42 Neutral | $128.21M | -1.14 | -39.64% | ― | ― | -6.70% |
* General Sector Average
AARD
Aardvark Therapeutics, Inc.
1.39
-9.31
-87.01%
KPTI
Karyopharm Therapeutics
0.52
-5.82
-91.85%
CUE
Cue Biopharma
18.66
-4.90
-20.78%
EQ
Equillium
1.23
-0.18
-12.77%
ADCT
ADC Therapeutics
1.44
-2.65
-64.79%
NKTX
Nkarta
1.79
-0.62
-25.73%
Aardvark Therapeutics, Inc. Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
Aardvark Therapeutics advances ARD-101 after FDA hold lift
Positive
Oct 23, 2026
On October 23, 2026, Aardvark Therapeutics reported exploratory efficacy and safety data from its previously terminated Phase 3 HERO trial and related open-label extension evaluating ARD-101 in Prader-Willi syndrome. The trial was halted after ran...
Business Operations and StrategyRegulatory Filings and Compliance
FDA Lifts Clinical Hold on Aardvark’s ARD-101 Program
Positive
Oct 22, 2026
On October 22, 2026, Aardvark Therapeutics announced that the U.S. Food and Drug Administration lifted the clinical hold on its Investigational New Drug application for ARD-101, a candidate for treating hyperphagia in patients with Prader-Willi Sy...
Business Operations and StrategyExecutive/Board Changes
Aardvark Therapeutics Adds Veteran Independent Board Director
Positive
Oct 8, 2026
On October 7, 2026, Aardvark Therapeutics appointed David (Zhongwei) Zhang, Ph.D., MBA, as an independent Class II director, adding a veteran clinical development and biostatistics leader with more than 25 years of experience across Abivax, Alumis...
Executive/Board ChangesShareholder Meetings
Aardvark Therapeutics Shareholders Approve Governance and Incentives
Positive
Aug 17, 2026
At its August 14, 2026 annual meeting, Aardvark Therapeutics, Inc. recorded a quorum with approximately 54.79% of outstanding shares represented, as stockholders voted on director elections, auditor ratification, and equity compensation matters. I...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.